Researchers argue that the national, centralized regulation of clinical artificial intelligence (AI) is not sufficient and instead propose a hybrid model of centralized and decentralized regulation.
In an opinion piece published in PLOS Digital Health, public health researchers at Harvard note that the increase in clinical AI applications, combined with the need to adapt applications to account for differences between local health systems, creates a significant challenge for regulators.
Currently, the US Food and Drug Administration (FDA) regulates clinical AI under the classification of software-based medical devices. Medical device approval is typically obtained via premarket clearance, de novo classification, or premarket approval. In practice, this usually involves the approval of a “static” model, meaning that any change in data, algorithm, or intended use after initial approval requires reapplication for approval. To receive approval, developers must demonstrate a model’s performance on an appropriately heterogeneous dataset.
Sécurité des mots de passe : bonnes pratiques pour éviter les failles La sécurité des…
Ransomware : comment prévenir et réagir face à une attaque Le ransomware est l’une des…
Cybersécurité et e-commerce : protéger vos clients et vos ventes En 2025, les sites e-commerce…
Les ransomwares : comprendre et se défendre contre cette menace En 2025, les ransomwares représentent…
RGPD et cybersécurité : comment rester conforme en 2025 Depuis sa mise en application en…
VPN : un outil indispensable pour protéger vos données Le VPN, ou « Virtual Private…
This website uses cookies.